Expanded Spectrum and Increased Incidence of Adverse Events Linked to COVID-19 Genetic Vaccines: New Concepts on Prophylactic Immuno-Gene Therapy, Iatrogenic Orphan Disease, and Platform-Inherent Challenges

Pharmaceutics, Год журнала: 2025, Номер 17(4), С. 450 - 450

Опубликована: Март 31, 2025

The mRNA- and DNA-based “genetic” COVID-19 vaccines can induce a broad range of adverse events (AEs), with statistics showing significant variation depending on the timing data analysis methods used. Focusing only lipid nanoparticle-enclosed mRNA (mRNA-LNP) vaccines, this review traces evolution statistical conclusions prevalence AEs incidents associated these from initial underestimation atypical, severe toxicities to recent claims suggesting possible contribution vaccinations excess deaths observed in many countries over past few years. Among hundreds different listed Pfizer’s pharmacovigilance survey, present categorizes main symptoms according organ systems, nearly all them being affected. Using US Vaccine Adverse Event Reporting System global vaccination dataset, comparison incidence rates induced by genetic versus flu revealed an average 26-fold increase use vaccines. difference is especially pronounced case ‘Brighton-listed’ AEs, which are also post-COVID conditions. these, increases relative given as x-fold rises, were 1152x, 455x, 226x, 218x, 162x, 152x, 131x for myocarditis, thrombosis, death, myocardial infarction, tachycardia, dyspnea, hypertension, respectively. delineates concept that be regarded prophylactic immuno-gene therapies chronic disabling might categorized iatrogenic orphan diseases. It examines unique vaccine characteristics could causally related abnormal immune responses potentially lead complications. These new insights may contribute improving safety platform technology assessing risk/benefit balance various products.

Язык: Английский

Targeting the complement system: notes on therapeutic strategies for renal cancer

Future Medicinal Chemistry, Год журнала: 2025, Номер unknown, С. 1 - 3

Опубликована: Апрель 25, 2025

Язык: Английский